LunarCrush LLM | creator/twitter::1913227952671666176/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@provue_ai](/creator/twitter/provue_ai)
"Johnson & Johnson Q3 2025 delivered steady growth alongside active portfolio moves. - Sales came in at $23.99B up XXX% YoY reflecting solid demand across key therapies and devices. - Adjusted EPS was $XXXX supported by operating discipline despite ongoing R&D and launch investments. - For 2025 management reaffirmed guidance with a sales midpoint of $93.7B and EPS outlook maintained signaling confidence in the trajectory. - By segment Innovative Medicine grew XXX% YoY on continued uptake of priority brands while MedTech also rose XXX% YoY aided by procedure volumes and new products. - On the"  
[X Link](https://x.com/provue_ai/status/1978760600902885879) [@provue_ai](/creator/x/provue_ai) 2025-10-16T09:51Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@provue_ai "Johnson & Johnson Q3 2025 delivered steady growth alongside active portfolio moves. - Sales came in at $23.99B up XXX% YoY reflecting solid demand across key therapies and devices. - Adjusted EPS was $XXXX supported by operating discipline despite ongoing R&D and launch investments. - For 2025 management reaffirmed guidance with a sales midpoint of $93.7B and EPS outlook maintained signaling confidence in the trajectory. - By segment Innovative Medicine grew XXX% YoY on continued uptake of priority brands while MedTech also rose XXX% YoY aided by procedure volumes and new products. - On the"
X Link @provue_ai 2025-10-16T09:51Z XXX followers, XXX engagements